This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
GSK to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.
GSKNegative Net Change JNJNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
NVAXNegative Net Change ZTSNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
MRKNegative Net Change MRNAPositive Net Change SMMTNegative Net Change
pharmaceuticals
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
pharmaceuticals
Company News for Apr 28, 2025
by Zacks Equity Research
Companies In The News Are: ABBV, SLB, CL, CHTR.
SLBPositive Net Change CLNegative Net Change CHTRNegative Net Change ABBVPositive Net Change
consumer-discretionary consumer-staples oil-energy pharmaceuticals
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
AZNPositive Net Change VRTXNegative Net Change EXELNegative Net Change ARGXNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
by Zacks Equity Research
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
RHHBYNegative Net Change JNJNegative Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Can Moderna Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
MRKNegative Net Change MRNAPositive Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.
NVAXNegative Net Change CTMXNegative Net Change ARGXNegative Net Change RXRXNo Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
GSKNegative Net Change GILDNegative Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Conflicting Claims on U.S./China Trade Sends Pre-Markets in the Red
by Mark Vickery
The closer we get to July 10th without a new trade deal, the more precarious these tariff charges become.
AMZNPositive Net Change AAPLPositive Net Change MSFTPositive Net Change CLNegative Net Change ANPositive Net Change LAZNegative Net Change ABBVPositive Net Change METANegative Net Change
auto-tires-trucks consumer-staples earnings pharmaceuticals
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
AMGNNegative Net Change NVAXNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
PFENegative Net Change ANIPNegative Net Change NCNANegative Net Change BNTXNegative Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.
AZNPositive Net Change IRTCPositive Net Change SOPHNegative Net Change TEMNegative Net Change
pharmaceuticals
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?
AZNPositive Net Change IRTCPositive Net Change SOPHNegative Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices pharmaceuticals
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
by Zacks Equity Research
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
AZNPositive Net Change MRKNegative Net Change ANIPNegative Net Change CTMXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
BMYNegative Net Change PFENegative Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
by Zacks Equity Research
RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.
REGNNegative Net Change RHHBYNegative Net Change NVOPositive Net Change LLYNegative Net Change
earnings pharmaceuticals
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
A Busy Morning: Jobless Claims, Durable Goods & Q1 Earnings
by Mark Vickery
While Jobless Claims and Durable Goods outperformed, we saw mixed results in Q1 earnings this morning.
INTCPositive Net Change BMYNegative Net Change CMCSAPositive Net Change FCXPositive Net Change PGNegative Net Change UNPNegative Net Change PEPNegative Net Change AALPositive Net Change GOOGLNegative Net Change
airlines consumer-discretionary earnings pharmaceuticals
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
by Zacks Equity Research
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
REGNNegative Net Change SNYNegative Net Change AZNPositive Net Change PFENegative Net Change
pharmaceuticals
Can Biogen Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
AZNPositive Net Change BIIBPositive Net Change SAGENegative Net Change STOKPositive Net Change
pharmaceuticals
Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA
by Shaun Pruitt
The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.
HCAPositive Net Change ABBVPositive Net Change
earnings hospitals investing medical oncology-screening pharmaceuticals
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
REGNNegative Net Change SNYNegative Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
AUPHNegative Net Change ESPRNegative Net Change HRTXNegative Net Change PSTVPositive Net Change PYXSNegative Net Change
pharmaceuticals